SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

AimedBio and Boehringer Ingelheim Begin Phase I Study of BI 4060107

The first patient has been dosed in the first-in-human study of the antibody-drug conjugate in people with advanced solid tumors.

Related stories